Mpox vaccine (No!)

葱蒜姜刺芹空心菜炒面 (Yes!) 

Quote:

The mpox/smallpox vaccine has been a major revenue driver for Bavarian Nordic. The vaccine generated DKK5bn ($724m) in revenue from global vaccine sales and government contracts last year, as per the company’s financials.

Another mpox vaccine in development is Moderna’s mRNA vaccine, currently being trialled in a Phase I/II study (NCT05995275). The trial is evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in healthy adults.

See:

Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial, October 29, 2024.

WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak, October 29, 2024.